Drugs that contain Nedosiran Sodium

1. Rivfloza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10738311 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US10351854 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US11359203 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US11053502 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US11661604 NOVO Methods and compositions for inhibiting expression of LDHA
Oct, 2038

(14 years from now)

US11286488 NOVO Methods and compositions for inhibiting expression of LDHA
Oct, 2038

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2028
Orphan Drug Exclusivity(ODE-443) Sep 29, 2030

NCE-1 date: 30 September, 2027

Market Authorisation Date: 29 September, 2023

Treatment: Method of treating primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION

More Information on Dosage

RIVFLOZA family patents

Family Patents